Nxera Pharma Co Stock

Nxera Pharma Co ROE 2024

Nxera Pharma Co ROE

-0.11

Ticker

4565.T

ISIN

JP3431300007

WKN

A0B7EK

In 2024, Nxera Pharma Co's return on equity (ROE) was -0.11, a -1,732.88% increase from the 0.01 ROE in the previous year.

Nxera Pharma Co Aktienanalyse

What does Nxera Pharma Co do?

The Sosei Group Corp. is a Japanese company that operates in the fields of pharmaceutical research and development. It was founded in 1990 as Photonamic GmbH & Co KG in Munich, Germany, before being renamed Sosei Co. Ltd. in 2003. The company is headquartered in Tokyo, Japan, and operates research and development facilities in Japan, the United Kingdom, and Denmark. Sosei is involved in several significant drug development projects and has produced some successful products in the past. Business model: The main focus of the Sosei Group Corp. is the research and development of pharmaceuticals. Its primary business model is to be involved in the entire value chain of drug development, from the discovery and characterization of new drug candidates to clinical development and regulatory approval. In order to attract partners in the pharmaceutical and biotech industry, the company offers its core competencies in drug research and development, including optimizing drug candidates and conducting clinical trials. Partnerships can be structured in the form of strategic alliances, licensing fees, milestone payments, and profit sharing. Divisions: The Sosei Group Corp. divides its activities into three main divisions: 1. Sosei Heptares: The company is a leading player in G-protein-coupled receptor (GPCR) research and development. GPCRs are a class of membrane proteins involved in regulating signal transduction processes and are of significant importance in drug development. Sosei Heptares provides its expertise and technology platform to third parties for developing new drugs targeting GPCR. 2. Sosei R&D: Sosei R&D focuses on the discovery and development of new drug candidates in various therapeutic areas, including inflammation, oncology, pain, respiratory, and mental disorders. The company utilizes its proprietary technology platform, which includes computer-aided design and synthesis optimization, to identify and develop new drugs. 3. Sosei CMC: The Sosei CMC department is responsible for developing customized processes for manufacturing pharmaceuticals. It encompasses all aspects of drug manufacturing, from formulation to manufacturing techniques. The department also works closely with other departments of the company to ensure that the drug products meet the highest quality and safety standards. Products: Sosei has developed and brought to market some successful drugs in the past. These include medications such as: 1. NVA237 (glycopyrronium bromide): An inhalation medicine for the treatment of chronic obstructive pulmonary disease (COPD). 2. QVA149 (indacaterol/glycopyrronium bromide): Another inhalation medicine approved for the treatment of COPD. 3. Sovodakso (GSK-491876): A drug candidate developed in partnership with GlaxoSmithKline (GSK) currently under investigation in phase III clinical trials for the treatment of schizophrenia. 4. Aclidinium bromide: An inhalation medicine for the treatment of COPD, developed in partnership with Almirall. In summary, the Sosei Group Corp. is a leading player in pharmaceutical research and development. The company focuses on developing novel drugs for the treatment of a variety of diseases and works closely with partners in the pharmaceutical and biotech industry. With its extensive knowledge and technological expertise, Sosei is one of the few companies capable of overcoming the challenges in drug development. Nxera Pharma Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Nxera Pharma Co's Return on Equity (ROE)

Nxera Pharma Co's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Nxera Pharma Co's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Nxera Pharma Co's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Nxera Pharma Co’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Nxera Pharma Co stock

What is the ROE (Return on Equity) of Nxera Pharma Co this year?

The ROE of Nxera Pharma Co this year is -0.11 undefined.

How has the Return on Equity (ROE) of Nxera Pharma Co developed compared to the previous year?

The ROE of Nxera Pharma Co has increased by -1,732.88% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Nxera Pharma Co?

A high ROE indicates that Nxera Pharma Co generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Nxera Pharma Co?

A low ROE can indicate that Nxera Pharma Co is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Nxera Pharma Co affect the company?

A change in ROE (Return on Equity) of Nxera Pharma Co can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Nxera Pharma Co?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Nxera Pharma Co?

Some factors that can influence Nxera Pharma Co's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Nxera Pharma Co pay?

Over the past 12 months, Nxera Pharma Co paid a dividend of 2.5 JPY . This corresponds to a dividend yield of about 0.23 %. For the coming 12 months, Nxera Pharma Co is expected to pay a dividend of 0 JPY.

What is the dividend yield of Nxera Pharma Co?

The current dividend yield of Nxera Pharma Co is 0.23 %.

When does Nxera Pharma Co pay dividends?

Nxera Pharma Co pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nxera Pharma Co?

Nxera Pharma Co paid dividends every year for the past 0 years.

What is the dividend of Nxera Pharma Co?

For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nxera Pharma Co located?

Nxera Pharma Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Nxera Pharma Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nxera Pharma Co from 6/24/2015 amounting to 10 JPY, you needed to have the stock in your portfolio before the ex-date on 3/27/2015.

When did Nxera Pharma Co pay the last dividend?

The last dividend was paid out on 6/24/2015.

What was the dividend of Nxera Pharma Co in the year 2023?

In the year 2023, Nxera Pharma Co distributed 0 JPY as dividends.

In which currency does Nxera Pharma Co pay out the dividend?

The dividends of Nxera Pharma Co are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Nxera Pharma Co

Our stock analysis for Nxera Pharma Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nxera Pharma Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.